Current Research

We design and execute HEOR analyses alongside prospective clinical trials, and perform retrospective analyses of major claims databases utilizing modern tools such as R, SAS, SQL, and others.  Our analysts are seasoned specialists in budget impact and cost-effectiveness modeling using Excel/VBA, TreeAge, and R/Shiny.

We collaborate with scientists, clinicians, and stakeholders from industry, health plans, and academia to answer the most pressing questions about healthcare value today.  Our research is published in leading scientific journals as well as presented at national and international conferences.

Current areas of research focus include:

• Aging and dementia
• Diabetes
• Depression
• Ocular disease, including glaucoma, diabetic retinopathy, and cataracts
• Infectious diseases and vaccine education programs
• Blood products, including plasma and platelet technologies
• Preterm birth

Current research partners include:

• Thomas Jefferson University
• Wills Eye Hospital
• University of Connecticut
• Johns Hopkins University
• Drexel University
• Brown University
• University of Rochester Medical Center
• GlaxoSmithKline
• Cerus Corporation
• Rutgers University Biostatistics & Epidemiology Services (RUBIES)

Among our partners is Rutgers University Biostatistics & Epidemiology Services (RUBIES).  RUBIES is a center within Rutgers Biomedical and Health Sciences and the Rutgers School of Public Health that provides statistical support, including design, programming, data management, and data analysis. RUBIES is a strategic partner of HOPE that provides advisement and analytical support from biostatistics faculty and analysts seasoned in working with healthcare data from primary sources (e.g., prospective studies) as well as secondary sources (e.g., large claims or medical record datasets). HOPE partners with RUBIES to conduct outcomes studies and, in turn, HOPE supports RUBIES by providing scientific support for research or models examining the cost or cost effectiveness of medical interventions.

Recent Publications

• Henderson M, Horton DB, Bhise V, Bushnell G, Dave CV. Trends in Healthcare Costs Among Commercially-Insured Adults and Children with Multiple Sclerosis in the United States, 2002-2021. JAMA Neurology (in press).

• Dave CV, Li Y, Steinman M, Lee SJ, Liu X, Jing B, Graham LA, Marcum ZA, Fung K, Odden MC. Initiation of antihypertensives and risk of fractures among older VA nursing home residents. JAMA Internal Medicine. 2024 184 (6), 661-669.

• Henderson M, Horton DB, Bhise V, Pal G, Bushnell G, Dave CV. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among U.S. Adults and Children, 2001-2020. JAMA Neurology. 2023 1;80(8):860-867.

• Liaw J, Harhay M, Setoguchi S, Gerhard T, Dave CV, Trends in prescribing preferences for antidiabetic medications among type 2 diabetes patients in the UK with and without chronic kidney disease, 2006-2020. Diabetes Care. 2022. 45.10: 2316-2325.

• Dave CV, Brittenham GM, Carson JL, Setoguchi S. Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study. Annals of Internal Medicine. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. 2022

• Dave CV, Kim SC, Goldfine A, Glynn R, Tong A, Patorno E. Risk of Cardiovascular Outcomes in Patients with Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation. 2021 Feb 23;143(8):770-779.

• Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018. Diabetes Care.2020 Apr;43(4):921-924

• Dave CV, Schneeweiss S, Patorno E. Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men. JAMA Internal Medicine. 2019 Sep 3;179(11):1587–90.

• Dave CV, Hartzema A, Kesselheim AS. Prices of Generic Drugs Associated with Numbers of Manufacturers. New England Journal of Medicine. 2017 Dec 28;377(26).

• Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High Generic Drug Prices and Market Competition: A Retrospective Cohort Study. Annals of Internal Medicine. 2017 Aug 1;167(3):145-151.

• Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E, Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infection events. Annals of Internal Medicine 2019 Aug 20;171(4):248-256.

• D’Arcy ME, Beachler DC, Pfeiffer RM, Curtis JR, Mariette X, Seror R, Mahale P, Rivera DR, Yanik EL, Engels EA.; Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis; Cancer Epidemiol Biomarkers Prev. 30(11):2059-2067, 2021

• Jayaraman P, Mosbruger T, Hu T, Tairis NG, Wu C, Clark PM, D’Arcy M, Ferriola D, Mackiewicz K, Gai X, Monos D, Sarmady M.; AnthOligo: automating the design of oligonucleotides for capture/enrichment technologies; Bioinformatics, 36(15):4353-4356, 2020

• D’Arcy ME, Castenson D, Lynch CF, Kahn AR, Morton LM, Shiels MS, Pfeiffer RM, Engels EA.; Risk of Rare Cancers Among Solid Organ Transplant Recipients; J Natl Cancer Inst.,113(2):199-207, 2021

• D’Arcy ME, Pfeiffer RM, Rivera DR, Hess GP, Cahoon EK, Arron ST, Brownell I, Cowen EW, Israni AK, Triplette MA, Yanik EL, Engels EA.; Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States; JAMA Dermatology,156(7):772-779, 2020

• D’Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, Morris CR, Rao C, Engels EA.; Survival after a cancer diagnosis among solid organ transplant recipients in the United States; Cancer, 125(6):933-942, 2019

• D’Arcy M, Stürmer T, Lund JL.; The importance and implications of comparator selection in pharmacoepidemiologic research; Curr Epidemiol Rep, 5(3):272-283, 2018

• Khosrow-Khavar F, Azoulay L, Montastruc F, Montastruc JL, Renoux C. Aromatase Inhibitors and Risk of Parkinsonism in Women Diagnosed with Breast Cancer: Population Based Cohort Study. Cancer, 2022 Apr 1. doi: 10.1002/cncr.34208.

• Khosrow-Khavar F, Kim, SC, Lee H, Lee S, Desai RJ. Tofacitinib and Risk of Cardiovascular Outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) Study. Ann Rheum Dis. 2022. doi: 10.1136/annrheumdis-2021-221915.

• Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Aromatase Inhibitors and Risk of Cardiovascular Disease in Women with Breast Cancer. Circulation,141(7): 549-559, 2020.

• Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Cardiotoxic Effects of Sequential Aromatase Inhibitors Use in Women with Breast Cancer. American Journal of Epidemiology, 89(10): 1086-1095, 2020.

• Khosrow-Khavar F, Yin H, Barkun A, Bouganim N, Azoulay L. Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer. Annals of Oncology, 29(3): 744-748, 2018.

• Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen Deprivation Therapy and Risk of Dementia in Patients with Prostate Cancer. Journal of Clinical Oncology, 35(2): 201-207, 2017.

• Ritchey ME, Girman C. Evaluating the feasibility of electronic health records and claims data sources for specific research purposes. Therapeutic Innovation & Reg Sci. 2020. PMID: 33258098

• Ritchey ME, West SL, Maldonado G. Validity of Pharmacoepidemiologic Drug and Diagnosis Data. In Strom B, Hennesey S, Kimmel S. Pharmacoepidemiology, 6th ed. Wiley. 2019; 948-90.

• Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, et al. Cardiovascular safety during and after use of phentermine and topiramate. J Clin Endocrinol Metab. 2019;104(2):513-22. PMID: 30247575

• Anthony MS, Armstrong MA, Getahun D, Scholes D, Gatz J, …, Ritchey ME, et al. Identification and validation of uterine perforation, intrauterine device expulsion, and breastfeeding in four health care systems with electronic health records. Clinical Epidemiol. 2019; 11:635-43. PMID: 31413641

• Brodovicz KG, Chen Y, Liu Z, Ritchey ME, Liao J, Engel SS. Characterization of Sitagliptinp Use in Patients with type 2 diabetes and chronic kidney diease by cross-sectional analysis of a medical insurance claims database. Diabetes Ther. 2015;6(4):627-634. PMID: 26438107

• Jalbert JJ, Ritchey ME, Mi X, Chen CY, Hammill BG, Curtis LH, Setoguchi S. Methodological considerations in observational comparative effectiveness research in implantable medical devices: an epidemiological perspective. Am J Epidemiol. 2014; 180(9):949-58. PMID: 25255810